In September 2016, the federal government made an unparalleled investment in research and innovation, announcing $84 million in funding over seven years for McGill’s Healthy Brains for Healthy Lives initiative, as part of the Canada First Research Excellence Fund (CFREF) program. Following this announcement, a committee for the selection of the HBHL Managing Director engaged in an extensive search and interview process. The Chair of the Selection Committee, Vice-Principal Rosie Goldstein, is now pleased to announce the appointment of Dr.
CQDM and Brain Canada join forces again in the funding of two new research projects to address unmet needs in brain research
CQDM and Brain Canada are proud to announce the funding of two new multi-disciplinary and multi-institutional research projects under the second edition of their Focus on Brain strategic initiative. The partners will award a total of $3M to two research teams to develop cutting-edge tools, technologies and platforms designed to accelerate the discovery of new drugs for brain and nervous system disorders.
An all-star lineup of experts in the fields of sports and neurology will share a stage on Jan. 27 to discuss concussions, a serious injury that has only recently been getting the attention it deserves.
The 85th Congrès annuel de l’Association francophone pour le savoir (Acfas) may be five months away, but McGill is already busy getting ready to host what is the largest French-language interdisciplinary conference in the world.
Researchers urged not to miss Nov. 1 deadline for colloquia proposals.
Have you ever met someone who just wasn’t into music? They may have a condition called specific musical anhedonia, which affects three-to-five per cent of the population.
Researchers at the University of Barcelona and the Montreal Neurological Institute and Hospital of McGill University have discovered that people with this condition showed reduced functional connectivity between cortical regions responsible for processing sound and subcortical regions related to reward.
Drug shown to reduce new attacks/symptom progression in some patients
In separate clinical trials, a drug called ocrelizumab has been shown to reduce new attacks in patients with relapsing remitting multiple sclerosis (MS), and new symptom progression in primary progressive MS.
Research Seminar - 'Doing PAR in Troubled Times' with Dr. Steven Jordan
Study tracks patients to better understand effects and possible treatments
December 1 is World AIDS Day, a time to raise awareness about a disease that has afflicted 70 million people worldwide, 35 million of whom have died as a result.
Researchers have linked a debilitating neurological disease in children to mutations in a gene that regulates neuronal development through control of protein movement within neuronal cells.
Two researchers at the Montreal Neurological Institute and Hospital (MNI) of McGill University have received funding to study a devastating neurodegenerative disease that first appears in toddlers just as they are beginning to walk.
MNI scientists will study stem cells, genetic mutations to develop new treatments
Researchers at the Montreal Neurological Institute of McGill University who are playing key roles in uncovering the mechanisms underlying ALS will share in $3.9 million in research funding, part of $4.5 million announced on Nov. 23 by the ALS Society of Canada in partnership with Brain Canada.
When two people smell the same thing, they can have remarkably different reactions, depending on their cultural background. Researchers at the Neuro have found that even when two cultures share the same language and many traditions, their reactions to the same smells can be different.
McGill University will receive more than $1.1 million for CBRAIN, one of the world’s most advanced computing platforms for brain research, through the Canada Foundation for Innovation’s (CFI) Cyberinfrastructure Initiative.
McGill University will launch an ambitious effort to advance understanding of the human brain and ease the burden of neurological and mental-health disorders, thanks to an $84 million, seven-year grant announced today under the federal government's Canada First Excellence Research Fund (CFREF).